December 1, 2010

Comparison of MammaPrint and TargetPrint Results with Clinical Parameters in German Patients with Early Stage Breast Cancer

Int J Mol Med. 2010 Dec;26(6):837-43.

Gevensleben H., Göhring U.J., Büttner R., Heukamp L.C., Kunz G., Dimpfl T., Jackisch C., Ortmann O., Albert U.S., Bender R., De Snoo F., Krijgsman O., Glas A.M., Ergönenc Y.H., Vogel C., Dykgers A., Langwieder C., Rees M., Anzeneder T.

Thirty-two percent of patients (19/59) with a poor prognosis-signature identified via MammaPrint did not receive adjuvant systemic treatment apart from endocrine therapy and were potentially undertreated; whereas 42% (35/77) of patients with a good prognosis-signature received chemotherapy and were potentially overtreated.

Read more: Gevensleben et al_2010_International Journal of Molecular Medicine_32% of Patients